The estimated Net Worth of David W Mc Faul is at least $3.52 Milión dollars as of 12 February 2010. David Faul owns over 2,795 units of Boston Scientific stock worth over $3,523,872 and over the last 17 years David sold BSX stock worth over $0.
Sign up
David Faul BSX stock SEC Form 4 insiders trading
David has made over 8 trades of the Boston Scientific stock since 2008, according to the Form 4 filled with the SEC. Most recently David exercised 2,795 units of BSX stock worth $231,817 on 12 February 2010.
The largest trade David's ever made was exercising 9,332 units of Boston Scientific stock on 30 October 2009 worth over $773,996. On average, David trades about 1,824 units every 43 days since 2007. As of 12 February 2010 David still owns at least 42,487 units of Boston Scientific stock.
You can see the complete history of David Faul stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's David Faul's mailing address?
David's mailing address filed with the SEC is ONE BOSTON SCIENTIFIC PLACE, , NATICK, MA, 01760-1537.
Insiders trading at Boston Scientific
Over the last 20 years, insiders at Boston Scientific have traded over $938,841,783 worth of Boston Scientific stock and bought 1,398,972 units worth $16,231,539 . The most active insiders traders include Peter M Nicholas, John E Abele a Michael F Mahoney. On average, Boston Scientific executives and independent directors trade stock every 3 days with the average trade being worth of $4,899,929. The most recent stock trade was executed by Michael F Mahoney on 5 September 2024, trading 162,777 units of BSX stock currently worth $13,212,609.
What does Boston Scientific do?
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.
What does Boston Scientific's logo look like?
Complete history of David Faul stock trades at Boston Scientific
Boston Scientific executives and stock owners
Boston Scientific executives and other stock owners filed with the SEC include:
-
Michael Mahoney,
Chairman of the Board, President, Chief Executive Officer -
Daniel Brennan,
Chief Financial Officer, Executive Vice President -
Joseph Fitzgerald,
Executive Vice President, President, Interventional Cardiology -
Edward Mackey,
Executive Vice President - Operations -
David Pierce,
Executive Vice President and President, MedSurg and President, Endoscopy -
Michael F. Mahoney,
Chairman, Pres & CEO -
Daniel J. Brennan,
Exec. VP & CFO -
Joseph M. Fitzgerald,
Exec. VP & Pres of Interventional Cardiology -
Edward F. Mackey,
Exec. VP of Global Operations -
Jeffrey B. Mirviss,
Exec. VP & Pres of Peripheral Interventions -
Edward Ludwig,
Lead Independent Director -
Charles Dockendorff,
Independent Director -
David Roux,
Independent Director -
John Sununu,
Independent Director -
Donna James,
Independent Director -
Nelda Connors,
Independent Director -
Ellen Zane,
Independent Director -
Stephen MacMillan,
Independent Director -
Yoshiaki Fujimori,
Independent Director -
John Sorenson,
Senior Vice President - Manufacturing and Supply Chain -
Meghan Scanlon,
Senior Vice President and President, Urology and Pelvic Health -
Scott Olson,
Senior Vice President and President, Rhythm Management -
Maulik Nanavaty,
Senior Vice President and President - Neuromodulation -
Wendy Carruthers,
Senior Vice President - Human Resources -
Desiree Ralls-Morrison,
Senior Vice President, General Counsel, Corporate Secretary -
Jodi Eddy,
Senior Vice President, Chief Information Officer -
Eric Thepaut,
Executive Vice President and President - Europe, Middle East and Africa -
Jeffrey Mirviss,
Executive Vice President and President - Peripheral Interventions -
Ian Meredith,
Executive Vice President, Global Chief Medical Officer -
Arthur Butcher,
Executive Vice President and President, Asia Pacific -
Catherine Jennings,
VP of Global Marketing & New Bus. Devel. of Peripheral Interventions -
Vance R. Brown,
Sr. VP, Gen. Counsel & Corp. Sec. -
Susan Vissers Lisa,
VP of Investor Relations -
Jodi Euerle Eddy,
Sr. VP and Chief Information & Digital Officer -
Jonathan R Monson,
VP, Global Controller & Chief Accounting Officer -
Vance R Brown,
SVP, GC and Corp. Secretary -
Timothy A. Pratt,
EVP & General Counsel -
Supratim Bose,
EVP & President, Asia-Pacific -
Michael P. Phalen,
SVP & President, Endoscopy -
Keith D Dawkins,
Sr. VP, Chief Medical Officer -
Kevin J. Ballinger,
EVP & Pres, Interven Cardio -
Cheryl Pegus,
Director -
David S Wichmann,
Director -
Xin Warren Wang,
SVP and Pres, Asia Pacific -
Peter M Nicholas,
Director -
Kristina M Johnson,
Director -
Nicholas J Jr Nicholas,
Director -
Karen Prange,
SVP&Pres, Uro & Women's Health -
Ernest Mario,
Director -
John E Abele,
Director -
Uwe E Reinhardt,
Director -
Katharine T Bartlett,
Director -
Jean Fitterer Lance,
SVP & Chief Compliance Officer -
Kenneth Pucel,
EVP, Operations -
Bruce L Byrnes,
Director -
John Michael Onuscheck,
SVP & Pres-Neuromodulation -
Jeffrey D Capello,
Chief Accounting Officer -
Otha T. Iii Spriggs,
SVP, Human Resources -
William Kucheman,
SVP & Group President -
John Raymond Elliott,
Director -
Lawrence R Neumann,
SVP and Pres, Emerging Markets -
John B. Pedersen,
Pres,Uro & Women's Health -
Brian R Burns,
SVP - Quality -
Ray J Groves,
Director -
Sam R Leno,
CFO & EVP Finance & IS -
Stephen F Moreci,
Sr. VP, Endosurgery -
Marye Anne Fox,
Director -
Fred Colen,
EVP -
John E Pepper,
Director -
James Gilbert,
EVP -
Donovan Paul,
SVP, Corporate Comm -
David W Mc Faul,
Senior VP International -
Ursula M Burns,
Director -
Warren B Rudman,
Director -
William F Jr Mcconnell,
SVP, Administration CRM -
Donald S Baim,
EVP, Chief Med. & Sci. Officer -
Lucia Luce Quinn,
Exec. Vice President-HR -
James R Tobin,
President & CEO -
Paul W Sandman,
EVP and General Counsel -
Paul A Laviolette,
COO -
Nancy Ann Deparle,
Director -
Joel Lawrence Fleishman,
Director -
David C Habiger,
Director -
Jonathan Monson,
SVP, Global Controller and CAO -
Emily Woodworth,
SVP, Global Controller and CAO -
Jessica L Mega,
Director -
Susan E Morano,
Director